Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel

Arthur C Houts; Daniel Hennessy; Mark S Walker; Leonardo Nicacio; Stephen F Thompson; Paul Je Miller; Bradley G Somer

doi:10.12788/jcso.0072

Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel

J Community Support Oncol. 2014 Sep;12(9):321-8. doi: 10.12788/jcso.0072.

Authors

Arthur C Houts¹, Daniel Hennessy², Mark S Walker³, Leonardo Nicacio², Stephen F Thompson², Paul Je Miller¹, Bradley G Somer⁴

Affiliations

¹ ACORN Research LLC, Memphis, Tennessee, USA.
² Sanofi US LLC, Bridgewater, New Jersey, USA.
³ ACORN Research LLC, Memphis, Tennessee, USA. mwalker@acorncro.com.
⁴ The West Clinic, Memphis, Tennessee, USA.

PMID: 25848909
DOI: 10.12788/jcso.0072

Abstract

Background: Treatment for metastatic castrate-resistant prostate cancer in community settings is not well understood.

Objective: To examine treatment patterns, sequencing, and outcomes in patients receiving second- and third-line treatment after first-line docetaxel.

Methods: We used a community oncology database to identify patients who progressed after line 1 docetaxel (D) and received line 2 cabazitaxel (DC), abiraterone (DA), or other therapy (DO). Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan- Meier and Cox regression models. Line 3 included subsets DCA and DAC.

Results: Line 2 groups (DC = 60 patients, DA = 71, DO = 153) did not differ significantly on demographic and clinical characteristics or median PFS on docetaxel therapy. Cox regression for OS by line 2 groups showed increased risk for DA compared with DC (HR, 1.69; P = .026) when 24 untreated DO patients were excluded. A similar nonsignificant pattern was observed when the 24 untreated patients were included. Of patients receiving DC in line 2, a nominally greater proportion received A in line 3 (57%, 34 of 60 patients) than did patients who received DA in line 2 followed by C in line 3 (25%, 18 of 71).

Limitations: There was a small sample for line 3, and unexamined confounds and selection biases in observational research. Conclusions Treatment patterns in community settings following docetaxel are complex and may involve multiple hormonal agents prior to disease progression. Cabazitaxel may not be optimally used in advanced disease. Although Cox regression showed increased risk of death for DA compared with DC, results need to be validated prospectively.

Conclusions: Treatment patterns in community settings following docetaxel are complex and may involve multiple hormonal agents prior to disease progression. Cabazitaxel may not be optimally used in advanced disease. Although Cox regression showed increased risk of death for DA compared with DC, results need to be validated prospectively.